Who's missing out? The truth behind food allergy treatment approvals
Mapping food allergy care with omalizumab and real-world data IgE-mediated food allergies (FAs)...
Mapping food allergy care with omalizumab and real-world data IgE-mediated food allergies (FAs)...
High-risk NMIBC: Disease overview and treatment approach Johnson & Johnson quickly identified and...
The one constant in healthcare marketing is change, particularly in four key areas: Evolving...
Our series exploring the value of real-world data (RWD) throughout the pharmaceutical product life...
Historically, pharmaceutical manufacturers leveraged retail pharmacy prescriptions to identify...
With the start of 2024, we are moving toward a world without third-party cookies to track consumer...
Healthcare brand marketing is at a crossroads. With patients taking a more active role in their...
As therapies become increasingly complex and personalized, it is imperative that physicians...
Alzheimer’s disease burden and the current therapy pipeline Alzheimer’s disease remains the leading cause of dementia, and the field is racing to turn clinical trial signals into care that changes daily life. What makes this moment different is bread...